Background: Neurodegeneration plays an important role in permanent disability in multiple sclerosis (MS). Objective: The objective of this paper is to determine whether progressive neurodegeneration occurs in MS eyes without clinically evident inflammation. Methods: Retinal nerve fiver layer thickness (RNFLT) and ganglion cell-inner plexiform layer thickness (GCIPT) were measured using Cirrus optical coherence tomography (OCT) in 133 relapsing-remitting MS (RRMS) patients (149 nonoptic neuritis (ON), 97 ON eyes, last ON ≥6 months). Ninety-three patients were scanned at two visits. Percentages of abnormal GCIPT vs RNFLT (<5% of machine norms) in cross-sectional data were compared. Relations between RNFLT/ GCIPT and MS duration (cross-sectional) and follow-up time (longitudinal) were assessed. Results: GCIPT was abnormal in more eyes than RNFLT (27% vs 16% p = 0.004 in non-ON, 82% vs 72% p = 0.007 in ON). RNFLT and GCIPT decreased with MS duration by −0.49 µm/yr (p = 0.0001) and −0.36 (p = 0.005) for non-ON; −0.52 (p = 0.003) and −0.41 (p = 0.007) for ON. RNFLT and GCIPT decreased with follow-up time by −1.49 µm/yr (p < 0.0001) and −0.53 (p = 0.004) for non-ON, −1.27 (p = 0.002) and −0.49 (p = 0.04) for ON. Conclusions: In RRMS eyes without clinically evident inflammation, progressive loss of RNFLT and GCIPT occurred, supporting the need for neuroprotection in addition to suppression of autoimmune responses and inflammation.
Introduction
Multiple sclerosis (MS), a chronic demyelinating and degenerative disease of the central nervous system (CNS), is the leading cause of nontraumatic neurological disability in young adults. The natural history of MS suggests that about 85% of patients initially experience a relapsingremitting course (RRMS) and within 25 years of onset a high percentage transition to a secondary progressive phase (SPMS) 1,2 with continuous neurological decline leading to permanent disability. 3 Currently available immuno-modulatory disease-modifying therapies (DMT) have been successful in reducing inflammation and relapses 4 and in slowing disease progression in RRMS. 5 However, a recent study of MS patients with 15 years' continuous use of an immune-modulatory drug reduced but did not eliminate progression to SPMS. 6 While it is generally agreed that permanent disability in MS is a consequence of irreversible axonal loss, 3 the underlying causes of MS and progression of the disease remain unclear.
MS eyes provide a unique opportunity to study axonal degeneration. The retinal ganglion cells (RGCs) and their naturally unmyelinated axons in the eye can be evaluated in vivo using spectral domain optical coherence tomography (OCT), a highly reproducible imaging technique. Inflammation of the optic nerve, i.e. optic neuritis (ON), is typically detectable with signs and symptoms such as eye pain, loss of vision, reduced color vision, swelling and presence of relative afferent pupillary defects. 7 In this study, retinal nerve fiber layer thickness (RNFLT) and retinal ganglion cell-inner plexiform thickness (GCIPT) were measured in two groups of "clinically silent" RRMS eyes: eyes without a history of ON (non-ON group) and those with a previous history of ON but the inflammatory event was at least six months prior to the onset of the present study (ON group). Separating the non-ON and ON groups allowed us to tease apart neurodegenerative effects that could be due to previous overt inflammatory episodes in ON eyes from those in non-ON eyes lacking a history of clinically evident inflammation. The change of RNFLT and GCIPT over time was analyzed cross-sectionally and longitudinally.
Methods

Subjects
One hundred thirty-one RRMS patients 8 from the University of Houston MS Eye CARE Clinic were included in the study. All patients underwent comprehensive eye examination by an experienced neuro-ophthalmologist. ON was diagnosed based on clinical signs and symptoms. 7 To minimize the effect of edema and other sequelae of acute inflammation, eyes with last ON attack within six months of the OCT measurement or between the baseline and follow-up measurements were excluded. Patients with ocular or systemic conditions other than ON/MS that could potentially influence OCT measures were excluded. Two hundred forty-seven eyes of 131 RRMS patients (85% on DMT) were included for cross-sectional analysis ( Table 1) . Seven eyes with acute ON, three with unclear ON history, three with other ocular abnormalities and two with OCT signal strength <7 were excluded. Twelve (seven non-ON and five ON) eyes did not have GCIPT. Among the 247 eyes, 241 had spherical equivalent refractive error (RE) less than −6.0D, 13 worse than −6.0D (range −6 to −15 D, median −7.5 D) and six eyes with unknown RE. Excluding these 19 eyes did not change the results reported below.
Ninety-two RRMS patients (164 eyes) from the crosssectional cohort had OCT at two different visits and were included for longitudinal analysis ( Table 2) . The time interval between the baseline and the follow-up visit ranged from two months to 3.8 years (median 1.0 years). For all eyes in the longitudinal cohort, OCT data from the second visit were reported in the cross-sectional analysis in order to include more eyes with longer duration of MS. Seven eyes with acute ON at the baseline, five with ON attack between two visits, four eyes with unclear ON history, one with other ocular abnormalities and three eyes with signal strength <7 in OCT in either of the visits were excluded. Fourteen (nine non-ON and five ON) eyes did not have GCIPT measured in one or both visits.
Procedures adhered to the tenets of the Declaration of Helsinki, and the protocol was approved by the University of Houston Committee for the Protection of Human Subjects.
OCT
OCT was performed using Cirrus-HD OCT 4000 version 6.5 (Carl Zeiss Meditec Inc, Dublin, CA) by a trained ophthalmic technician. Peripapillary RNFLT was acquired with the Optic Disc Cube 200 × 200 protocol that images the optic disc in a 6 mm x 6 mm region. The mean RNFLT and those from individual quadrants were obtained. Macular GCIPT was obtained using the Macular Cube 512 × 128 protocol that images a 6 mm × 6 mm area centered at the fovea. The GCIPT was derived automatically by the machine software over an elliptical annulus (2 mm × 2.4 mm radius), excluding the central foveal region (0.5 mm × 0.6 mm radius). In this paper, RNFLT and GCIPT refer to the overall mean unless a quadrant is specified. Only images with signal strength ≥7 and good centration were included. No OCT outputs had erroneous segmentation upon visual inspection.
Statistics
Statistical analyses were performed using SAS 9.2 (SAS Institute Inc, Cary, NC). For the cross-sectional data, RNFLT and GCIPT were each defined as abnormal if the values were below 5% of their respective age-matched machine norms. The percentage of eyes with abnormal RNFLT was compared to that of GCIPT using McNemar test. The relation between RNFLT/GCIPT and MS duration (cross-sectional data), RNFLT/GCIPT change and followup time (longitudinal data) were analyzed using the GENMOD procedure with generalized estimating equation (GEE) to account for age and intra-subject inter-eye correlation. The probability of an abnormal RNFLT and GCIPT as a function of MS duration was modeled using GEE logistic regression. P values less than 0.05 were considered statistically significant.
Results
Cross-sectional analysis
Reduced RNFLT and GCIPT in non-ON and ON eyes. One hundred thirty-one RRMS patients (149 non-ON, 98 ON eyes) with MS duration ranging from <1 month to 32 years were included for cross-sectional analysis ( Table 1 ). The mean (±SD, µm) RNFLT (75.0 ± 14.0) and GCIPT (65.5 ± 11.9) in ON were significantly thinner than in non-ON eyes (RNFLT: 88.6 ± 11.5, GCIPT: 76.5 ± 9.2, p < 0.0001 for both). Both non-ON and ON eyes had significantly thinner measures compared to normative RNFLT (92.8 ± 9.4 µm) and GCIPT (82.1 ± 6.2 µm) for Cirrus OCT 9 (p < 0.0001 for all comparisons). Twenty-five percent of ON eyes (n = 25) had more than one ON episode in the same eye (recurrent ON) and the mean RNFLT and GCIPT (µm) in these eyes were significantly thinner (67.1 ± 10.9 and 59.4 ± 11.9) than in eyes with single ON attacks (77.3 ± 14.1 and 67.3 ± 11.2, p < 0.001for both).
Linear regression between RNFLT/GCIPT and MS duration.
To determine the effects of long-term MS on neuronal loss, we performed linear regression between RNFLT/GCIPT and MS duration using a GEE model to correct for age and intra-subject inter-eye correlation ( Figure 1 ). RNFLT decreased at a mean rate (µm/year) of −0.49 (p = 0.0001, Figure 1 (a)) in non-ON and −0.52 (p = 0.002, Figure 1 (b)) in ON, and these two slopes were not significantly different (p = 0.90). To examine whether RNFLT loss in non-ON eyes was influenced by an ON history in the fellow eye, we analyzed bilateral non-ON eyes (n = 95) separately; which showed a slope of −0.37 µm/year, not different from that for all non-ON eyes (p = 0.56). In ON eyes, thinner RNFLT with longer MS might be partially attributed to more recurrent ON events over time. Interestingly, eyes with only one episode of ON (n = 73) showed a slightly steeper slope (−0.88 µm/year) than that of the whole ON group (−0.52 µm/year) although they were not significantly different (p = 0.17). RNFLT in individual quadrants also decreased with MS duration in non-ON and ON eyes ( Table 3 , cross-sectional data on the left). GCIPT decreased with MS duration at a mean rate (µm/year) of −0.36 (p = 0.005, Figure 1 (c)) in non-ON and −0.41 (p = 0.007, Figure 1(d) ) in ON, and these two slopes were not different (p = 0.81). GCIPT slope (µm/year) for bilateral non-ON eyes was −0.33 (p = 0.02) and single ON eyes was −0.67 (p < 0.0001).
Abnormalities in GCIPT/RNFLT and logistic regression.
It is of clinical interest to detect neuronal loss on an individual basis, and to account for the effects of normal aging we examined RNFLT and GCIPT from individual eyes and classified them as abnormal if the values were below 5% of their respective age-matched machine norms. Notably, more eyes showed abnormal GCIPT than RNFLT ( Table 4 ). Percentage of eyes showing abnormal GCIPT vs RNFLT was 27% vs 16% (p = 0.004) in non-ON and 82% vs 72% (p = 0.007) in ON. GCIPT also was abnormal in more eyes than RNFLT when only the temporal quadrant of RNFLT, the receiving region for the macular fibers, was considered, 27% vs 15% (p = 0.008) in non-ON and 82% vs 66% (p = 0.003) in ON eyes. To examine whether more abnormal RNFLT/GCIPT existed in eyes with longer MS duration, we performed a logistic regression using MS duration as a continuous independent variable and the status of RNFLT/ GCIPT (normal or abnormal) as a categorical dependent variable. In non-ON eyes, the probability of abnormal GCIPT increased significantly with MS duration (p = 0.03, Figure 2(a) ), however, for RNFLT the relation failed to reach statistical significance (p = 0.56). In ON eyes, the probability of abnormal RNFLT (Figure 2(b) ) and GCIPT (Figure 2(c) ) both increased significantly with MS duration (p = 0.01 for RNFLT, p = 0.02 for GCIPT). (Figure 3(a) ) and −1.27 (p = 0.002) in ON (Figure 3(b) ) and the slopes were not different (p = 0.64). To eliminate any possible effect of having ON history in the fellow eye, we analyzed bilateral non-ON eyes (n=53) separately. The rate of RNFL loss was −1.6, not different from that (−1.49) for all non-ON eyes (p = 0.83). RNFLT in individual quadrants also decreased with followup time in non-ON or ON eyes (nasal and temporal quadrant in ON did not reach statistical significance) ( Table 3 , longitudinal data on the right). GCIPT decreased with follow-up time at a rate (µm/year) of −0.53 (p = 0.004) in non-ON ( Figure 3c ) and −0.49 (p = 0.04) in ON (Figure 3(d) ) and the slopes were not different (p = 0.90). The rate of GCIPT loss in bilateral non-ON eyes was −0.69, not different from that (−0.53) for all non-ON eyes (p = 0.56). The association between RNFLT/GCIPT reduction and followup time remained significant for non-ON and ON eyes even after accounting for other co-variables such as age, MS duration, baseline RNFLT and time from last ON event (for ON eyes only) ( Table 5 ). 
Humphrey Visual Field (HVF) in cross-sectional and longitudinal analyses
No association was found between HVF mean deviation (MD) and MS duration in cross-sectional analysis (Figures  4(a) HVF MD probably did not show a significant association with duration of disease or follow-up time because of the large inter-subject variability in our study (Figures 4(a) and (b)) and the previously documented poor repeatability in ON eyes. 12
Discussion
Our results clearly indicate that progressive loss of RNFLT and GCIPT occurs in the absence of clinically evident inflammation in RRMS eyes. Progressive neuronal loss observed in non-ON eyes was not due to effects from ON in the contralateral eye as indicated by similar results in bilateral non-ON eyes. In the current study, the rates of change in RNFLT in cross-sectional (around −0.5 µm/year both for non-ON and ON eyes) and longitudinal data (−1.49 µm/ year in non-ON and −1.27 µm/year in ON eyes) are both greater than that of the normal age-related loss reported for Cirrus HD OCT: −0.19 µm/year in one cross-sectional study, 13 −0.37 µm/year in another, 14 and −0.52 µm/year in a longitudinal study. 15 It is interesting to note that the rate of change in RNFLT obtained from cross-sectional analysis is less than that from longitudinal analysis both for normal and MS subjects. This emphasizes that rate comparison is reasonable only among studies with similar designs. The rate of change in RNFLT may not be a constant throughout the entire disease course, therefore caution should be exercised in extrapolating results from a short time interval to long-term effect. In our previous unpublished study using Stratus OCT, we obtained similar findings. The rate of GCIPT loss in our cross-sectional data was about −0.4 µm/year both for non-ON and ON eyes, about 2.8 times the rate of normal aging (−0.14 µm/year) as reported in Mwanza et al.'s cross-sectional study of normal subjects between 18 and 84 years of age, their Figure 6 (a). 9 The rate of GCIPT loss in our longitudinal analysis (−0.49 µm/year in non-ON and −0.53 µm/year in ON eyes) was about 60% greater than −0.32 µm/year reported by Leung et al. 15 in normal subjects. Similarly, Ratchford et al. 16 reported a GCIPT loss of −0.37 µm/year in MS and −0.20 µm/year in normal individuals. As previously reported, 17 the rate of neuronal loss was similar for non-ON and ON eyes, indicating that documented acute inflammatory episodes had little impact on the rate of progression six months beyond the event.
Consistent with linear regression, our logistic regression analysis showed that the proportion of abnormal eyes with respect to GCIPT significantly increased with MS duration. By 30 years of MS, more than 50% of the non-ON eyes and 100% of the ON eyes would have significantly thinner GCIPT compared to age-matched normal individuals.
MS is traditionally viewed as a primary autoimmune disease in which inflammatory T cells cross the blood-brain barrier and attack the CNS, causing demyelination and axonal degeneration. 18 Recently, Stys et al. 19 proposed that cytodegeneration of oligodendrocyte-myelin complex and underlying axons could be the primary event, and antigenic debris released as a consequence promotes a secondary inflammatory immune response in a susceptible host. 19 Our finding that in the absence of clinically evident inflammation neurodegeneration progresses over time supports the possibility of primary neurodegenerative process in MS. However, we could also explain our results based on the primary autoimmune model, considering that there might be undetectable subclinical episodes of ON and/or chronic low-level inflammation in the optic nerve. Though there is evidence of subclinical demyelination as demonstrated by delayed latency of visual evoked potentials in non-ON MS eyes, 20 the presence of subclinical demyelination per se does not prove that the initiating trigger is autoimmune in nature, as it could also be interpreted as primary degeneration of myelin and underlying axons without sufficient antigenic myelin debris to initiate a secondary inflammatory immune response. 19 RGC axonal loss could also result from retrograde degeneration from lesions in the optic tract and/ or posterior visual pathway. In our study, none of the subjects showed homonymous visual field defects characteristic of optic tract lesion, although optic tract lesions could also be asymptomatic. 21 Lesions in the optic radiations could potentially lead to loss of RGC axons/neurons via retrograde transynaptic degeneration. Although there is some recent evidence of transynaptic degeneration in patients with acquired occipital lobe/optic radiation damage due to stroke, 22 this is yet to be demonstrated in MS.
In our study, more eyes showed abnormal GCIPT than mean or temporal RNFLT. GCIPT is likely more sensitive for detecting abnormal eyes (values outside of the norms) because it has less normal variation than RNFLT. In the normal population, the distribution of GCIPT had smaller coefficient of variation (CoV) (7.6%) than mean RNFLT (10%) and temporal RNFLT (16%) (calculated from Mwanza et al. 13 ). Anatomically, the intersubject variability for RGC counts is lowest in the parafoveal region, but highest at far superior and inferior retina, predicting larger variability in peripapillary axons than central RGC counts. 23 For OCT, differences in optic nerve head size, blood vessel patterns and glial content across normal subjects may also contribute to higher variability in RNFLT.
In fact in MS eyes it has been shown that GCIPT is less confounded by axonal edema and gliosis 24, 25 and therefore correlates better with visual dysfunction, 26 clinical and radiological markers of disease activity 16 than RNFLT. Another possibility is that RGC somas atrophy before the axons even though in retrograde degeneration, axonal pathology/dysfunction precedes that of the ganglion cell body. Fairless et al. 27 demonstrated in a rat model of MS that at the time of significant RGC soma loss, the axons appeared to be intact in numbers but showed ultrastructural signs of degeneration. Recent studies in glaucoma demonstrated the value of measuring macular RGCs. 28 Compared to temporal RNFLT, GCIPT measurements are more reproducible 10, 11 and might be a better measure to reflect macular damage. Therefore we believe that GCIPT is a great addition to tests for detecting and tracking neuronal changes in MS eyes. 16, 26 In fact, in our longitudinal data, more non-ON eyes showed worsening based on GCIPT than RNFLT (see data points below the lower test-retest variability limits in Figures 3(a) and (c)).
In summary, our data showed increased loss of RNFLT and GCIPT with increase in MS duration and follow-up time. There were significantly more abnormal eyes in the GCIPT measurements than in the RNFLT measurements both for non-ON and ON eyes. Progressive neuronal loss, in the absence of clinically evident inflammation, suggests a significant role for neurodegeneration in RRMS, traditionally viewed as an autoimmune disease. New therapeutic options should focus on remyelination and neuroprotection in addition to reducing inflammation and relapses.
